Brain-computer interfaces and AI cognitive enhancements are moving from labs toward human trials globally. Regulators worldwide face pressure to decide whether these technologies should follow pharmaceutical approval timelines or move faster like consumer electronics. This choice will shape accessibility and safety standards for billions.